Bringing a p53 hotspot mutation into reach of a T cell engager
Mutations in TP53 occur across many cancers, yet the intracellular location of the p53 protein makes it difficult to target with traditional antibody-based therapies. However, mutant peptides, including those derived from p53, can be displayed by human leukocyte antigen (HLA) molecules on the cancer cell surface as peptide-HLA (pHLA) complexes, offering a route to selectively target intracellular mutant proteins. While potentially attractive, these pHLA complexes are often scarce on tumor cells and differ from their normal counterparts by only one amino acid, making selective recognition technically challenging.
Authors
- Jacqueline Douglass (ORCID: https://orcid.org/0000-0002-9113-7090)
Institutions
- Howard Hughes Medical Institute (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Molecular Therapy Oncology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1016/j.omton.2026.201379
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Society of Clinical Oncology
- National Cancer Institute